Source: China – South China Morning PostChina’s medical products regulator approved the use of the country’s first locally developed neutralising antibody cocktail therapy for Covid-19 on Wednesday.Brii Biosciences said its therapy showed an 80 per cent reduction of hospital admissions and death in a global phase 3 trial with 847 non-hospitalised coronavirus patients, adding that no serious adverse events were identified.The National Medical Products Administration granted approval for the combination of two antibodies to be used for…Read More